Healthcare >> CEO Interviews >> June 15, 2000
GARY L. SNABLE is President & CEO and Director of Layton BioScience,
Inc. Mr. Snable has over 30 years experience in the pharmaceutical
industry with Richardson-Merrell, Inc., Fujisawa-SmithKline Corporation,
Invitron Corporation, and now Layton BioScience, Inc. With Fujisawa-
SmithKline, he was responsible for the growth of the company from an
initial staff of four to a staff of over 70, with sales in the United
States in excess of $25 million. At Invitron, Mr. Snable was responsible
for introducing Invitron Technology to pharmaceutical and biotechnology
companies worldwide and for successfully negotiating major agreements
with a number of leading firms. Mr. Snable helped found Layton
BioScience in 1991. The company is currently conducting clinical trials
to evaluate the effectiveness of LBS-Neurons_, human neuronal cells, to
treat fixed neurological deficits resulting from stroke. The effort to
repair brain damage caused by trauma or disease is a focus of Layton
BioScience. The importance of this therapeutic strategy is becoming
evident as the Phase IIa trial has demonstrated safety and feasibility
with a trend toward efficacy in restoring lost motor function. Layton
purchased Inversine' from Merck and has re-introduced Inversine' in the
US. Layton is conducting clinical trials to evaluate the efficacy of
Inversine' in a number of psychiatric disorders. Profile
BioScience?
Mr. Snable: Layton was founded in 1991 with a focus on the discovery and
development of therapeutics for treating
